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Abstract: Complex I (nicotinamide adenine dinucleotide (NADH): ubiquinone oxidoreductase) is
the largest complex of the mitochondrial oxidative phosphorylation system (OXPHOS) system.
Forty-four subunits encoded in nuclear and mitochondrial genomes compose this multiprotein
complex, its assembly being a highly complex process involving at least 15 additional nuclear encoded
assembly factors. Complex I deficiency is a mitochondrial disorder usually associated with early-onset
severe multisystem disorders characterized by highly variable clinical manifestations. Flavin adenine
dinucleotide (FAD)-dependent oxidoreductase domain-containing protein 1 (FOXRED1) is a complex
I assembly factor. To date, only five patients with mitochondrial complex I deficiency due to mutations
in FOXRED1 have been characterized. Here, we describe a child with ataxia, epilepsy and psychomotor
developmental delay carrying two heterozygous FOXRED1 variants, c.920G>A (p.Gly307Glu) and
c.733+1G>A. We demonstrate the molecular mechanism supporting the pathogenicity of the FOXRED1
variants, showing a clear deficiency of complex I activity. The reduction in the steady-state level of
complex I holoenzyme in patient fibroblasts, confirmed the pathogenicity of the variants and showed
the molecular mechanism behind their pathogenicity. A comparison of the clinical presentation of the
index case with the previously described cases allowed deepening our knowledge about the clinical
variability associated with FOXRED1 defects.
Keywords: mitochondrial disorders; complex I deficiency; FOXRED1; epilepsy
1. Introduction
Mitochondrial diseases (MDs), caused by defects in the mitochondrial oxidative phosphorylation
system (OXPHOS), are one of the most common inborn errors of metabolism with a birth prevalence of
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1/5000 [1,2]. Among these, complex I deficiency (MIM #252010) is the most common defect, accounting
for 1/3 of all cases [2].
The OXPHOS system, composed of five multi-subunit enzyme complexes and two electron carriers
(ubiquinone and cytochrome c), is the main cellular source of energy through ADP phosphorylation
to ATP using the electrochemical proton gradient generated by electron transport [3]. Mitochondrial
complex I, the major entry point for electrons to the respiratory chain [4], is the first and largest complex
of the OXPHOS system [5], and it consists of 44 different subunits codified by nuclear and mitochondrial
genes [6,7]. This complex plays a central role in energy metabolism: it has been implicated in the
regulation of reactive oxygen species (ROS) and is suggested as the rate-limiting step in overall
respiration [4]. Complex I assembly is proposed to involve a stepwise process with intermediate
complexes shared by two assembly pathways: de novo synthesis headed by mtDNA-encoded subunits
and the dynamic exchange of newly imported nDNA-encoded subunits with pre-existing components
of the mature complex [8–10].
The complicated assembly of so many subunits requires a number of assembly factors that are not
part of the final structure of complex I. Currently, at least 15 known or putative complex I assembly
factors have been described and variants in nine of these were associated with isolated complex I
deficiency due to impaired complex I biogenesis [9,11,12]. One of those assembly factors is FOXRED1,
a 486-amino acid FAD-dependent oxidoreductase. Initially, phylogenetic profiling and subsequent
knockdown studies identified FOXRED1 as a candidate protein for complex I biogenesis [13]. Later,
Formosa et al. confirmed its role not only in the assembly but also in the stability of late stages complex
I intermediates [14].
Complex I deficiency is involved in early-onset severe multisystem disorders [15,16] and represents
the biochemical phenotype for ~30% of mitochondrial disease pediatric patients [16]. The clinical
symptoms that arise are usually highly heterogeneous, with a poor prognosis, and rapid progression [17].
To date, only five patients with mitochondrial Complex I deficiency due to mutations in FOXRED1
have been described [18–22]. All the variants identified are located in the same protein domain. Here,
we demonstrate the molecular mechanism supporting the pathogenicity of the FOXRED1 variants
found in compound heterozygosity in our patient. Also, we compare the particular clinical presentation
of the patient with the previously described cases, expanding the phenotype spectrum associated with
FOXRED1 defects.
2. Experimental Section
This study was developed in collaboration with the University Clinical Hospital of Santiago de
Compostela (Spain) and Radboud University Medical Center (Netherlands). Parents have provided
written informed consent for study participation and the publication of the results. All experimental
protocols were approved by the Radboud University Medical Center and were performed in accordance
with relevant guidelines and regulations.
2.1. Clinical Profile
Our index case, Patient 1, a second child from nonconsanguineous parents, showed intrauterine
growth restriction (IUGR) from the first trimester of pregnancy. At 2 months, he was admitted to
the hospital for bronchiolitis. From that moment, his parents noticed he was less reactive. Magnetic
Resonance Imaging (MRI) of the brain was normal. At 3 months of age, the patient began to have
paroxysmal episodes and later showed a language delay. At 2 years old, he showed 5/6 episodes per
day of “blanking out” for a short period, with or without clonic movements. He was controlled with
oxcarbazepine. In the following year, he presented with loss of muscle tone and started to decline.
At 4 years old, he showed loss of awareness and responsiveness episodes with a fixed gaze; had clonic
movements of the right leg, 30–40 episodes of sudden falling per day and ataxia. Lactic acidosis was
present even without exercise. Currently, at 15 years old, the hypomotor episodes are still present.
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He has some difficulties adapting to new situations. He is more alert and more responsive but clumsier
and more uncoordinated with motor movements (complete clinical history in Supplementary Table S1).
2.2. Targeted Next-Generation Sequencing
The patient’s DNA was isolated from lymphocytes and analyzed with targeted next generation
sequencing (NGS) panels for mitochondrial diseases. We designed a multi-gene panel consisting of 150
nuclear genes coding for respiratory chain complex subunits and proteins involved in the OXPHOS
system function previously reported in the literature.
The genetic data was analyzed through NGS technology consistent in enrichment with an
in-solution hybridization technology (Sure Select XT; Agilent Technologies) and subsequent sequencing
in the Miseq platform (Illumina). A custom Sure Select probe library was designed to capture the
exons and exon–intron boundaries of the targeted genes [23]. Sequence capture, enrichment, and
elution were performed according to the manufacturer’s instructions. Image analysis and processing
of the fluorescence intensities in sequences (“Base Calling”) was performed with Real-Time Analysis
(RTA) software v.1.8.70 (Illumina), and quality control of the data was developed with FastQC v0.10.1
program. Reads were aligned to the reference genome GRCh37 with BWA v0.7.9a [24]. NGSrich
v0.7.5 software [25] was used as a control previous to variant detection, and BEDTools 2.17.0 [26]
and Picard 1.114 [27] for intermediate steps. VarScan v.2.3.6 [28] and SAMtools v0.1.19 [29] were the
variant detection software used for indels and single nucleotide polymorphisms (SNP), respectively
and Annovar for variant annotation [30].
To achieve a reliable clinical interpretation of the variants detected, we applied prioritization
criteria to predict their pathogenicity according to American College of Medical Genetics and Genomics
(AMCG) guidelines [31].
2.3. Protein Modeling
The FOXRED1 gene encodes a 486-amino acid FAD-dependent oxidoreductase domain-containing
protein. The protein has a cleavable N-terminal mitochondrial targeting sequence which was shown to
be localized to the mitochondrion [32] and associated with the matrix face of the mitochondrial inner
membrane [14].
The FOXRED1 (Uniprot AC: Q96CU9; ID: FXRD1_HUMAN) protein FASTA sequence was used
to build a protein model generated by SWISS-MODEL. The SWISS-MODEL template library (SMTL
version 2019-02-28, PDB release 2019-02-22) was searched with BLAST (Basic Local Alignment Search
Tool) [33] and HHBlits (Markov models (HMMs)–based lightning-fast iterative sequence search) [34]
for evolutionary-related structures matching the target sequence. By performing this homology model,
we tried to determine how the missense mutation detected in both patients may change the protein
structure, which most probably leads to local conformational changes inducing an important impact
on its function.
2.4. Cell Culture
Patient and healthy control fibroblasts were cultured in M199 medium (Gibco) supplemented
with 10% v/v fetal calf serum (FCS) and 1% v/v penicillin/streptomycin (Gibco) at 37 ◦C with 5% CO2.
2.5. Mitochondrial Isolation
Fibroblast pellets from both patients and control cell lines were resuspended in ice-cold 10 mM
Tris-HCl, pH 7.6. Cells were then disrupted in a Potter–Elvejhem homogenizer at 1800 rpm,
and sucrose was added to make the samples isotonic (250 mM). The homogenized cellular samples
were centrifugated for 10 min at 600× g and the mitochondria pellets were obtained after centrifugation
of the supernatant for 10 min at 14,000× g.
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2.6. Respirometry and OXPHOS Activity
The Seahorse XFe96 Extracellular Flux analyzer (Seahorse Bioscience, Billerica, MA, USA) was
used to measure Oxygen Consumption Rate (OCR) and the Extracellular Acidification Rate (ECAR).
In the day prior to the assay, control and patient fibroblasts were seeded at 10,000 per well in cell culture
medium (M199 supplemented with 10% FCS and 1% pen/strep) and incubated overnight at 37 ◦C with
5% CO2. On the assay day, the cell culture medium was replaced by Agilent Seahorse XP Base Medium
with 10 mM glucose (Sigma, St. Louis, MO, USA), 1 mM sodium pyruvate (Gibco), and 200 mM
L-glutamine (Life sciences) and then incubated for one hour at 37 ◦C without CO2. Baseline cellular
OCR was measured eight times followed by four measurement cycles after the addition of the following
inhibitors: 1 µM oligomycin A (Sigma), 2.0 µM and 4.0 µM carbonyl cyanide 4-(trifluoromethoxy)
phenylhydrazone FCCP (Sigma), and 0.5 µM rotenone and 0.5 µM antimycin A (Sigma), respectively.
After OCR measurements, the cell medium was removed and replaced by 0.33% Triton X-100, 10 mM
Tris-HCl (pH 7.6). Seahorse plates were stored at −80 ◦C and thawed afterward. To measure citrate
synthase, 3 mM acetyl-CoA, 1 mM DTNB, and 10% Triton X-100 were added. Citrate synthase activity
was measured spectrophotometrically, at 37 ◦C, using a Tecan Spark spectrophotometer. Measurements
were based on the absorption at 412 nm by the product thionitrobenzoic acid (TNB), and citrate
synthase activity was calculated from the rate of dithionitrobenzoic acid (DTNB) conversion in the
presence of oxaloacetate. OCR was measured before and after the addition of inhibitors and normalized
to citrate synthase activity according to Srere et al. [35].
The enzymatic activities of complexes I–V, citrate synthase and protein were assayed
spectrophotometrically as previously described [36]. All assays were performed in duplicate using a
Konelab 20XT auto-analyzer (Thermo Fisher Scientific, Waltham, MA, USA).
2.7. SDS-PAGE and BN-PAGE Immunoblot Analysis
For the detection of FOXRED1 protein and the native mitochondrial complex I in our patient and
control cell lines, SDS-PAGE and blue native page immunoblot analysis were performed, respectively.
Mitochondrial fractions from patient and control cell lines were used. For SDS-PAGE, samples were
heated and denaturated at 70 ◦C in the presence of β-Mercaptoethanol and separated on a 10% sodium
dodecyl sulfate-polyacrylamide gel. For blue-native PAGE, the native mitochondrial complexes
were solubilized with 2% w/w n-dodecyl β-d-maltoside. A total of 15 ug and 25 ug of solubilized
mitochondrial protein were separated on a 6–16% precast Native PAGE Bis-Tris gels (Invitrogen).
Subsequently, proteins were transferred to Immuno-Blot Polyvinylidene difluoride (PVDF) membranes
(0.20µm Immobilon-P (Millipore IPVH00010)) and immunodetection was performed with the following
antibodies: Rabbit polyclonal FOXRED1 antibody (Proteintech:24595-1-AP); CI-NDUFa9 (ab14713,
Abcam, Cambridge, UK); CII-SDHA (Ab14715; Abcam, Cambridge, UK); Secondary antibodies
goat anti-mouse (P0047; DAKO) and goat anti-rabbit (A00160, Genscript, Piscataway, NJ, USA).
The chemiluminescence signal was visualized using the enhanced chemiluminescence kit (ECL,
Thermo Fischer Scientific) and the Chemidoc XRS+ system (Biorad, Hercules, CA, USA).
3. Results
3.1. Molecular Genetics and in Silico Analysis of FOXRED1 Variants
Through NGS analysis, two compound heterozygous variants in FOXRED1 (NM_017547.3) were
identified in our patient (Figure 1). The variant c.920G>A (p.Gly307Glu), previously reported associated
with mitochondrial complex I deficiency, and a splicing variant, c.733+1G>A, not reported so far in
human genetic variation databases. Segregation studies were performed through Sanger sequencing
to determine the inheritance pattern, and the results are shown in Figure 1. The missense variant was
inherited from the mother, and the splicing variant was inherited from the father. The patient has an
older brother who also inherited both FOXRED1 variants and shows a similar, although milder, clinical
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phenotype (clinical history for both patient and brother, patients 1 and 2 respectively, in Supplementary
Table S1).
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Figure 1. Reverse sequence chromatograms showing Sanger sequencing results. The missense variant
c.920G>A (p.Gly307Glu), located in exon 8, was inherited from the mother and the splicing variant,
c.733+1G>A, located in intron 6, was inherited from the father. The patient and affected brother
harbored both variants in FOXRED1 in a compound heterozygous condition.
The FOXRED1 variants were analyzed in silico to determine the evolutionary conservation,
predicted pathogenicity, functional consequences and Minor Allele Frequency (MAF) within the
population (Supplementary Table S2). Ac ording to Genomic Evolutionary Rate Profiling (GERP),
PhyloP, and phastCons, both va iants a in positions of the FOXRED1 protein which are highly
conserved through evolution Pathogenicit was predicted as disease causing by MutationTast r
and damaging by FATHMM (Functional Analysis through H dden Markov Models) and DANN
(Deleterious Annotation of gene ic vari nts using N ural Networks) scores. The missense variant
c.920G>A is located in exon 8 a d results in a amino acid change from a non-polar glyc e to an acidic
negatively ch rged glutamic acid at residue 307 and it was predicted as tolerated b SIFT (Sorting
Intolerant From Tolerant) and damaging by Prove . The splicing variant .733+1G>A, located in
intron 6, was predict d to destroy the wild-type splice donor site, thus most probably affecting splicing.
3.2. FOXRED1 Protein Modeling
All the variants identified so far are located in different regions of the protein and are displayed in
the FOXRED1 domain structure (Figure 2A). In Figure 2B, model structures for FOXRED1 with and
without the mutation c.920G>A (p.Gly307Glu) are represented. As shown in the image, highlighted
with a red arrow, it seems that the missense mutation which induces the change of the non-polar amino
acid Glycine to the negatively charged Glutamic acid, displaces the spatial protein structure. In this
specific region of the protein loop (red arrow), positively charged amino acids such as Arginine and
Lysine are present, and non-polar methionine. The quaternary structure of FOXRED1 changes induced
by p.G307E mutation can impact the protein function and, therefore, the susceptibility for disease.
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Figure 2. (A) Domain structure of FOXRED1 with all the variants identified in the described
cases. In light blue, the cleavable mitochondrial targeting sequence is shown or displayed.
DAO—FAD-dependent oxidoreductase. (B) FOXRED1 protein modeling wild-type and FOXRED1
protein modeling with the m tation p.G307E, reflecting the predicted consequences in the spatial
protein structure due to the change of t e non-polar ami o acid Glycine to the negatively charged
Glutamic acid.
3.3. Mitochondrial Respiration and OXPHOS Activity
Measurements of OCR and ECAR were performed as well. Significant reductions of both OCR and
ECAR in our patient cell line were observed, indicating reduced electron flow through the respiratory
chain (Figure 3A,B). These results reflect the deficiency of the cumulative proficiency of the whole set
of mitochondrial respiratory chain complex s in patient fibroblasts. Spectrophotometric analysis of
respiratory chain enzyme activities r veal d an isolated eficiency of compl x I (82% of the lowest
value of the control ran e) in fibroblasts from the patient with normal activities of compl xes II, III, IV,
and V (Figur 3C).
3.4. SDS-PAGE and BN-PAGE Immunoblot Analysis
In F gure 3D, th presence of FOXRED1 protein is shown by SDS-PAGE. Immunoblot analysis of
one-dimensional Blue-Native polyacrylamide gel electrophoresis (BN-PAGE) gels showed a marked
reduced steady-state level of complex I holoenzyme in patient fibroblasts mitochondria (Figure 3E).
Different amounts of samples were used, 15 and 25 ug, respectively, and in both cases, there is a clear
deficiency of complex I in fibroblasts cells when comparing to control cell lines.
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Figure 3. (A) Oxygen Consumption Rate (OCR) is mea ured before and after the ddition of inhibitors.
The Seahorse XF Cell Mito Stress Test uses compounds of respirati n that target components of th
Electron Transport Chain (ETC) in the mitochondria to reveal key paramete s of metabolic function.
Th se modulators are ETC inhibitors (oligomycin, FCCP, and a mix of rotenone and anti ycin A) which
were seriall i jected to measure ATP (adenosine triphosphate) productio , maximal respiration (Max
Resp), non-mitoch drial respiration (Non-Mito Resp), proton leak, spare respiratory capacity (SRC)
and basal respiration (Basal Resp). (B) The basal energy metabolism of each cell line was assessed
by analyzing OCR/ECAR ratios through sequential injections of the inhibitors. (C) Measurement
of enzyme activities for the different oxidative phosphorylation system (OXPHOS) complexes in
patient and control fibroblasts. FOXRED1 migrated at its predicted size of 54 kDa. CS—Citrate
synthase. (D) SDS-PAGE immunodetections of FOXRED1 in control and patient fibroblasts. (M) Marker,
(C) Control, and (P) Patient. Blot was cropped from different parts of the same gel to show results from
samples of interest. A full-length gel is included in Supplementary Material. (E) One-dimensional
Blue-Native polyacrylamide gel electrophoresis (BN-PAGE) analysis of complex I in gel activity and
western blot immunodetection showing differences in complex I amount between control (C) and
patient (P) fibroblasts. Blot was cropped from different parts of the same gel to show results from
samples of interest. A full-length gel is included in Supplementary Material.
4. Discussion
In this work, we have presented the data supporting the pathogenicity of the compound
heterozygous FOXRED1 variants identified in our patient and his brother, in which the splicing
mutation c.733+1G>A is reported for the first time. The molecular characterization using the
patient’s fibroblasts clearly demonstrated a mitochondrial dysfunction due to abnormal mitochondrial
respiration with a significant decrease in the OCR/ECAR ratio, OXPHOS activity and reduced complex I.
The genetic results of all the cases described so far, including those presented in this work, are consistent
with a recessive mode of inheritance. All the FOXRED1 pathogenic variants identified lead to a loss of
complex I activity and mitochondrial disease.
Patients who show complex I deficiency due to defects in nuclear genes usually have a severe
clinical presentation and are associated with early age of death [11]. Pathogenic variants in FOXRED1,
a nuclear gene which encodes an assembly factor of complex I, seem to challenge this observation.
Most of the patients harboring FOXRED1 pathogenic variants survived to late childhood and adulthood
(Supplementary Table S1). Formosa et al. suggested that variants in this gene can result in FOXRED1
partial loss of function and the pathogenic variants are probably hypomorphic [14]. However, Apatean
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et al. have recently described a clinical case of a female patient, with two variants in the FOXRED1 gene
(c.612_615dupACTG (p.Ala206fsX15) and c.874G>A (p.Gly292Arg)) who died at 3 months with severe
pulmonary hypertension and lactic acidosis [21]. From the five patients reported in the literature,
Calvo et al. and Apatean et al. give a detailed description of the patients’ clinical presentation, and,
as is expected in complex I deficiency, both presented congenital lactic acidosis [19,21]. Our index case
and his brother have shown not only a later onset of clinical symptoms but also a later onset of lactic
acidosis and the latter has shown mild lactic acidosis as a result of exercise. They both show a less
serious clinical presentation in comparison with the previously published cases. Their psychomotor
development was not as severely affected as the reported patients. In addition, besides sharing the same
FOXRED1 pathogenic variants, both siblings show great clinical differences between them regarding
their quality of life. The youngest, our index case, has lower muscular tone, latent strabismus of the
right eye, fewer repetitive crises, low schooling, needs to nap for hours and takes 9 g of bicarbonate
per day plus supplements. The older brother has a normal life, with no muscular or visual difficulties,
with a normal school attendance although with certain behavioral alterations and learning disorders
and he never had a crisis. This clinical variability on disease severity associated with FOXRED1
mutations can be interpreted as a result of incomplete penetrance, a residual function of the FOXRED1
protein and/or other factors controlling gene expression.
Furthermore, FOXRED1 has been proposed to be a dual function protein: an assembly factor
for complex I biogenesis and a key enzyme of amino acid metabolism [37]. As a member of the
D-amino acid oxidases, FOXRED1 is functional as an oxidoreductase, and it is hypothesized that
this protein can participate in glycine metabolism, which in turn modulates glutathione biosynthesis,
an antioxidant protecting the cells from Reactive Oxygen Species (ROS) [32,38]. As previously stated,
complex I is the major entry point for electrons into the respiratory chain and also a major producer of
ROS species. Mitochondrial disorders are often conditions of oxidative stress (e.g., Leigh syndrome,
epilepsy) and symptoms can arise as a result of a functional deficiency that has an assembly factor,
reducing complex I activity with a significant increase in ROS species, and, on the other hand, as a result
of metabolic activity deficiency, leading to glutathione depletion and preventing the correct cellular
ROS detoxification. It could be that depending on the mutation location in FOXRED1, the impact
on the quaternary structure of the protein and, therefore, in its loss of function, can affect complex
I assembly and/or metabolic activity of the ROS species in different forms, influencing the clinical
severity spectrum of these disorders. Further studies are needed to elucidate how both functions could
be interacting with the molecular mechanism of the disorders associated with FOXRED1 dysfunction.
Overall, in this work we describe two cases of complex I deficiency due to FOXRED1 pathogenic
variants and discuss how FOXRED1 variants may cause a broad clinical spectrum and be associated with
different levels of disease severity—from the severe clinical presentation of patient 6, a three-month-old
girl who died from disease complications to the mild presentation of patient 2, the brother of our
index case. We demonstrated that the compound heterozygous variants identified were clearly
associated with complex I deficiency. More research work is needed to achieve a deep understanding
of the relationship between the molecular mechanism and disease progression. This will help in the
development of future therapeutic treatments by focusing on specific therapeutic agents, since the
responsiveness to a certain treatment may depend on specific gene mutations.
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